UnitedHealth Group Incorporated

UnitedHealth Group reported adjusted earnings per share of $6.38, compared with $4.08 in the prior year. Total revenues were $112 billion, largely consistent with the prior year, and operating earnings were $8 billion, up 55% year over year. The reported medical care ratio was 86.7% versus 89.4% in 2Q 2025, including $860 million of net favorable prior period medical development. Days claims payable were 47 days, up about 2.5 days year over year, and the operating cost ratio was 12.7% versus 12.3% a year ago. For 2026, management raised adjusted EPS guidance to $19.50-$20, expects a full-year medical care ratio of 88.1% ± 25 basis points, and now sees full-year share repurchases of at least $5 billion versus initial guidance of $2.5 billion.

Stephen Hemsley framed the quarter as evidence of more consistent execution and said the company is working to modernize the health system through affordability, transparency, simplicity, and AI. He emphasized that UnitedHealth is focusing not just on earnings growth but on improving how consumers and care providers experience healthcare, including by reducing prior authorization burden and making service more reliable and faster. His tone was confident and purposeful, but he repeatedly stressed that this is still early and that the company has “much more work ahead.”

Wayne DeVeydt said the quarter reflected improved performance across the business and highlighted the hard numbers behind the beat: $6.38 adjusted EPS, $112 billion in revenue, $8 billion in operating earnings, and 86.7% medical care ratio. He pointed to $11 billion of operating cash flow in the quarter, or 1.9x net income, and said the company had used $4 billion for repurchases through mid-July, with at least $5 billion now expected for 2026. He also noted the dividend was raised to $9.28 per share annualized and debt-to-capital improved to 41.2%, with a path toward roughly 40% by year-end.

Analysts focused on the gap between stronger Medicare/Optum performance and still-pressured commercial and Medicaid economics. Management said Medicaid remains within the previously communicated margin range of -1% to -1.7%, with rate actions running around 6%-7% annually but still lagging medical trend. On commercial, management said costs are modestly above 11%, driven by the No Surprises Act IDR process, provider coding intensity, and specialty drug costs, and said commercial margin recovery is now likely to extend beyond 2027. Questions also probed whether AI can lift long-term margins; management responded that AI is already improving prior auth, claims automation, call-center productivity, and clinician workflows, with benefits expected to compound into 2027 and 2028.